查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1998716

前列腺特异性抗原检测市场机会、成长驱动因素、产业趋势分析及预测（2026-2035年）

Prostate-Specific Antigen Test Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035
出版日期: | 出版商: Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球前列腺特异性抗原检测市场预计到 2025 年将价值 51 亿美元，预计到 2035 年将以 7.1% 的复合年增长率增长至 101 亿美元。

前列腺癌发病率的上升、PSA检测技术的不断进步以及全球诊断实验室基础设施的完善推动了市场扩张。 PSA检测透过测量前列腺产生的一种蛋白质的水平，有助于早期发现前列腺癌、监测疾病进展和评估治疗效果。高灵敏度检测、自动化免疫检测系统以及检测准确性的提升等技术创新，增强了临床对PSA检测的信心。 PSA密度、PSA速率和反射性检测等其他技术也提高了诊断准确性，并促进了其在临床实践中的更广泛应用。业界正在转向基于风险的筛检策略，将PSA检测整合到先进的诊断流程中，以在早期发现和最大限度减少过度诊断之间取得平衡。年龄、种族、家族病史、基准PSA水平和合併症等因素正日益影响检测决策，使PSA检测更具针对性和治疗意义。

初步筛检作为广泛应用的初步筛检工具，预计到2025年将占据68%的市场。总PSA、游离PSA比值和初级筛检组合通常用于在建议进行侵入性检查前评估癌症风险。由于这些检测经济有效、易于取得且非侵入性，因此有助于临床医生对患者进行风险分层，避免不必要的切片检查，从而支持更安全的临床决策。

市场范围
开始年份 2025
预测年份 2026-2035
起始金额 51亿美元
预测金额 101亿美元
复合年增长率 7.1%

预计到2025年，摄护腺癌筛检市占率将达到53.5%，到2035年将达到51亿美元。 PSA检测在早期发现前列腺癌方面继续发挥着至关重要的作用，尤其是在老龄化社会中，并推动了其在定向筛检和大规模筛检计画中的应用。政府和机构对有组织的筛检倡议的支持正在减少经济和后勤方面的障碍，从而进一步提高筛检率。

预计到2025年，北美前列腺特异性抗原（PSA）检测市场份额将达到36.9%，主要驱动因素包括前列腺癌高发病率、男性人口老化以及人们对早期检测意识的提高。医院、专科诊所和诊断实验室已将PSA检测纳入常规筛检计画。先进的医疗基础设施，包括一流的检查室和即时检测设施，以及对下一代检测方法的巨额投资，正在推动PSA检测在该地区快速普及和广泛应用。

目录

第一章：调查方法

  • 研究途径
  • 品质改进计划
    • GMI人工智慧政策和资料完整性倡议
      • 资讯来源一致性通讯协定
  • 调查过程和可靠性评分
    • 调查过程的组成部分
    • 评分组成部分
  • 数据收集
    • 主要来源部分列表
  • 资料探勘资讯来源
    • 付费资讯来源
      • 区域资讯来源
  • 基本估算和计算方法
    • 每种方法中基准年的计算
  • 预测模型
    • 量化市场影响分析
      • 生长参数对预测的数学影响
  • 关于调查透明度的补充信息
    • 资讯来源归属框架
    • 品质保证指标
    • 对信任的承诺

第二章执行摘要

第三章业界考察

  • 产业生态系分析
  • 影响产业的因素
    • 成长驱动因素
      • 摄护腺癌发生率增加
      • 个人化医疗和预防性诊断的普及
      • 诊断检测和就地检验。
      • 提高对早期检测和筛检的认识
    • 产业潜在风险与挑战
      • 先进的PSA检测技术高成本
      • 特异性低和假阳性导致的过度诊断
    • 市场机会
      • 开发下一代多标记诊断平台
      • 家庭和分散式检查解决方案的成长
  • 成长潜力分析
  • 监理情势
    • 北美洲
    • 欧洲
    • 亚太地区
  • 科技趋势
    • 当前技术趋势
    • 新兴技术
  • 救赎方案
  • 未来市场趋势
  • 2025年价格分析
  • 波特五力分析
  • PESTEL 分析
  • 客户洞察
  • Start-Ups场景
  • 投资环境
  • 差距分析

第四章 竞争情势

  • 介绍
  • 企业矩阵分析
  • 企业市占率分析
    • 世界
    • 北美洲
    • 欧洲
    • 亚太地区
  • 竞争定位矩阵
  • 主要市场公司的竞争分析
  • 主要进展
    • 併购
    • 伙伴关係与合作
    • 新产品发布
    • 业务拓展计划

第五章 市场估价与预测：依产品划分，2022-2035年

  • 初步检查
    • 总摄护腺特异性抗原检测
    • 联合前列腺特异性抗原检测
    • 游离前列腺特异性抗原检测
  • 确认性试验
    • 切片检查
    • 经直肠超音波检查
    • PCA3 测试

第六章 市场估计与预测：依应用领域划分，2022-2035年

  • 摄护腺癌筛检
  • 前列腺癌的后续观察

第七章 市场估计与预测：依最终用途划分，2022-2035年

  • 医院
  • 诊断中心
  • 专科诊所
  • 其他最终用户

第八章 市场估计与预测：依地区划分，2022-2035年

  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国

第九章：公司简介

  • Abbott
  • AdvaCare Pharma
  • Beckman Coulter
  • BIOMERIEUX
  • CTK Biotech
  • DiaSorin
  • Fujirebio
  • Intec
  • KOELIS
  • Labcorp
  • mdxhealth
  • Myriad Genetics
  • OPKO Health
  • Roche
  • SIEMENS Healthineers
简介目录
Product Code: 7136

The Global Prostate-Specific Antigen Test Market was valued at USD 5.1 billion in 2025 and is estimated to grow at a CAGR of 7.1% to reach USD 10.1 billion by 2035.

The market's expansion is fueled by the increasing prevalence of prostate cancer, ongoing technological advancements in PSA testing, and the growth of diagnostic laboratory infrastructure worldwide. PSA tests measure the level of a protein produced by the prostate gland, aiding in the early detection of prostate cancer, monitoring disease progression, and assessing treatment outcomes. Technological innovations, such as high-sensitivity assays, automated immunoassay systems, and improved test accuracy, have strengthened clinical confidence in PSA testing. Additional methods, including PSA density, PSA velocity, and reflex testing, enhance diagnostic precision, supporting broader clinical adoption. The industry is moving toward risk-based screening strategies, integrating PSA testing with advanced diagnostic workflows to balance early detection with minimizing overdiagnosis. Factors such as age, ethnicity, family history, baseline PSA levels, and comorbidities increasingly guide testing decisions, making PSA testing more targeted and therapeutically relevant.

The preliminary tests segment held 68% share in 2025 owing to its widespread use as an initial screening tool. Total PSA, free PSA ratio, and first-line screening panels are commonly employed to evaluate cancer risk before recommending invasive procedures. These tests are cost-effective, accessible, and non-invasive, helping clinicians stratify patients and avoid unnecessary biopsies, thereby supporting safer clinical decisions.

Market Scope
Start Year2025
Forecast Year2026-2035
Start Value$5.1 Billion
Forecast Value$10.1 Billion
CAGR7.1%

The prostate cancer screening segment held a 53.5% share in 2025 and is projected to reach USD 5.1 billion through 2035. PSA testing continues to play a crucial role in early detection, particularly in aging populations, driving its adoption in both targeted and population-based screening programs. Government and institutional support in organized screening initiatives reduces financial and logistical barriers, further increasing test uptake.

North America Prostate-Specific Antigen Test Market accounted for 36.9% share in 2025, driven by the high incidence of prostate cancer, an aging male population, and strong awareness of early detection. Hospitals, specialty clinics, and diagnostic laboratories routinely incorporate PSA testing into standard screening programs. Advanced healthcare infrastructure, including state-of-the-art laboratories and point-of-care facilities, along with high investment in next-generation assays, facilitates rapid adoption and widespread availability of PSA tests in the region.

Key players in the Global Prostate-Specific Antigen Test Market include Abbott, AdvaCare Pharma, Beckman Coulter, BIOMERIEUX, CTK Biotech, DiaSorin, Fujirebio, Intec, KOELIS, Labcorp, mdxhealth, Myriad Genetics, OPKO Health, Roche, and SIEMENS Healthineers. Companies in the Global Prostate-Specific Antigen Test Market are employing multiple strategies to strengthen their market foothold. They focus on product innovation, developing highly sensitive, automated, and user-friendly assays for accurate early detection and monitoring. Strategic partnerships with hospitals, diagnostic labs, and healthcare networks expand distribution and adoption. Investment in R&D ensures next-generation technologies, improved assay performance, and regulatory compliance. Geographic expansion into high-growth regions increases market penetration, while marketing campaigns emphasize accuracy, reliability, and clinical relevance. Firms also provide training and technical support to laboratories and clinicians to enhance usage and build long-term customer loyalty, thereby solidifying their competitive positioning.

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Research approach
  • 1.2 Quality commitments
    • 1.2.1 GMI AI policy & data integrity commitment
      • 1.2.1.1 Source consistency protocol
  • 1.3 Research trail & confidence scoring
    • 1.3.1 Research trail components
    • 1.3.2 Scoring components
  • 1.4 Data collection
    • 1.4.1 Partial list of primary sources
  • 1.5 Data mining sources
    • 1.5.1 Paid sources
      • 1.5.1.1 Sources, by region
  • 1.6 Base estimates and calculations
    • 1.6.1 Base year calculation for any one approach
  • 1.7 Forecast model
    • 1.7.1 Quantified market impact analysis
      • 1.7.1.1 Mathematical impact of growth parameters on forecast
  • 1.8 Research transparency addendum
    • 1.8.1 Source attribution framework
    • 1.8.2 Quality assurance metrics
    • 1.8.3 Our commitment to trust

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Product trends
    • 2.2.3 Application trends
    • 2.2.4 End use trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing incidence of prostate cancer
      • 3.2.1.2 Adoption of personalized healthcare and preventive diagnostics
      • 3.2.1.3 Technological advancements in diagnostic assays and point-of-care testing
      • 3.2.1.4 Rising awareness of early detection and screening
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High cost of advanced PSA testing technologies
      • 3.2.2.2 Limited specificity and false positives leading to overdiagnosis
    • 3.2.3 Market opportunities
      • 3.2.3.1 Development of next-generation and multi-marker diagnostic platforms
      • 3.2.3.2 Growth in home-based and decentralized testing solutions
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
  • 3.5 Technology landscape
    • 3.5.1 Current technological trends
    • 3.5.2 Emerging technologies
  • 3.6 Reimbursement scenario
  • 3.7 Future market trends
  • 3.8 Pricing analysis, 2025
  • 3.9 Porter's analysis
  • 3.10 PESTEL analysis
  • 3.11 Customer insights
  • 3.12 Start-up scenarios
  • 3.13 Investment landscape
  • 3.14 Gap analysis

Chapter 4 Competitive Landscape, 2025

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
    • 4.3.1 Global
    • 4.3.2 North America
    • 4.3.3 Europe
    • 4.3.4 Asia Pacific
  • 4.4 Competitive positioning matrix
  • 4.5 Competitive analysis of major market players
  • 4.6 Key developments
    • 4.6.1 Mergers & acquisitions
    • 4.6.2 Partnerships & collaborations
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2022 - 2035 ($ Mn)

  • 5.1 Key trends
  • 5.2 Preliminary tests
    • 5.2.1 Total prostate specific antigen test
    • 5.2.2 Complex prostate specific antigen test
    • 5.2.3 Free prostate specific antigen test
  • 5.3 Confirmatory tests
    • 5.3.1 Biopsy
    • 5.3.2 Trans-rectal ultrasound
    • 5.3.3 PCA3Test

Chapter 6 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

  • 6.1 Key trends
  • 6.2 Prostate cancer screening
  • 6.3 Prostate cancer monitoring

Chapter 7 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Diagnostic centers
  • 7.4 Specialty clinics
  • 7.5 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE

Chapter 9 Company Profiles

  • 9.1 Abbott
  • 9.2 AdvaCare Pharma
  • 9.3 Beckman Coulter
  • 9.4 BIOMERIEUX
  • 9.5 CTK Biotech
  • 9.6 DiaSorin
  • 9.7 Fujirebio
  • 9.8 Intec
  • 9.9 KOELIS
  • 9.10 Labcorp
  • 9.11 mdxhealth
  • 9.12 Myriad Genetics
  • 9.13 OPKO Health
  • 9.14 Roche
  • 9.15 SIEMENS Healthineers